Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | 25-year benefit from tamoxifen by clinically used breast cancer markers

Huma Dar and Linda Lindström, MSc, PhD of the Karolinska Institute, Stockholm, Sweden, discuss the findings of a secondary analysis of the STO-3 trial, which aimed to determine the value of clinically used biomarkers in the prediction of long-term survival outcomes in patients with breast cancer. In the STO-3 trial patients with lymph node-negative and ER+/HER2- breast cancer received tamoxifen therapy. The study reported that tumor size and grade are significant predictive factors for 25-year distant recurrence-free interval (DRFI) outcome. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.